Obesity-Linked HS
When HS occurs alongside obesity, the assumption is often that weight is the cause. In reality, both conditions share a common internal environment: insulin resistance, metabolic inflammation, and hormonal disruption. Addressing weight alone does not resolve HS — and understanding why this is the case changes what treatment must actually do.
Obesity and HS are not cause and effect — they are co-expressions of the same underlying metabolic and inflammatory dysfunction
Insulin resistance is the central shared driver: it sustains androgen excess, chronic inflammation, and immune dysregulation simultaneously
Weight loss, where it occurs, can improve the disease environment — but does not correct the internal processes driving active HS
The metabolic dimension of obesity-linked HS requires direct, system-level correction — not lifestyle advice alone
Why Obesity and HS Co-Exist — and Why Weight Is Not the Whole Story
The relationship between obesity and HS is real but frequently misunderstood. Most patients with obesity-linked HS are told that losing weight will resolve their condition. Many lose weight and find their HS continues. This is not a failure of effort — it reflects a misunderstanding of the biology involved.
What Obesity and HS Actually Share
Both obesity and HS are driven, in significant part, by the same internal environment: insulin resistance, chronic low-grade inflammation, and hormonal disruption — particularly androgen excess. These are not consequences of each other in a simple linear way. They are co-expressions of a shared metabolic state.
Adipose tissue — particularly visceral fat — is metabolically active. It produces inflammatory cytokines, disrupts insulin signalling, and contributes to androgen production through peripheral conversion. This creates conditions that worsen HS directly, independent of friction or mechanical factors.
This explains why obesity-linked HS tends to be more severe, more multifocal, and harder to control with surface treatment: the internal inflammatory and hormonal environment is more persistently disturbed.
Why Weight Loss Alone Is Not Sufficient
Weight loss improves the metabolic environment — and this matters. Patients who achieve sustained weight reduction often notice some improvement in HS activity. However, weight loss does not directly correct insulin resistance, normalise androgen levels, or restore gut and immune function. These processes require targeted correction, not just caloric reduction.
Furthermore, HS itself makes sustained weight loss harder. Pain and lesion location restrict movement. Psychological impact reduces motivation. The inflammatory burden of active HS sustains insulin resistance. This creates a cycle where HS worsens the metabolic state and the metabolic state worsens HS.
Effective treatment must work on both sides of this cycle — not focus on one end while expecting the other to follow automatically.
Common Framing
"Your weight is causing your HS"
This framing implies that weight loss will resolve the condition — and places responsibility on the patient's behaviour. It oversimplifies the biology, creates unnecessary blame, and leads to treatments that do not address the actual drivers. Many patients experience this framing as dismissive of the severity of their condition.
Accurate Understanding
"Obesity and HS share a common internal environment"
This framing identifies the actual target: the metabolic and inflammatory state that drives both conditions. Treatment focuses on correcting insulin resistance, reducing systemic inflammation, and restoring hormonal balance — which addresses HS activity directly and also supports sustainable metabolic improvement over time.
How Metabolic Dysfunction Sustains HS — Step by Step
Understanding why obesity-linked HS keeps recurring requires following the chain of events from metabolic dysfunction to skin expression. Each step in this chain is a potential point of correction — and each step ignored is a reason recurrence continues.
Insulin Resistance — The Central Disruption
Insulin resistance — where cells respond inadequately to insulin signalling — sits at the centre of the obesity-linked HS mechanism. It drives compensatory hyperinsulinaemia: chronically elevated insulin levels that have systemic inflammatory consequences. From an Ayurvedic perspective, this maps onto a disruption of Agni (metabolic fire) at the tissue level — where the body's ability to correctly process and utilise energy breaks down, generating an accumulating metabolic burden.
Androgen Excess — The Hormonal Cascade
Hyperinsulinaemia directly stimulates androgen production — both through ovarian and adrenal pathways. Elevated androgens drive increased sebum production, alter follicular keratinisation, and create the structural vulnerability in hair follicles that is central to HS lesion formation. This is why obesity-linked HS so frequently overlaps with PCOS and why it tends to affect hormonally active sites — underarm, groin, under-breast — with particular severity.
Adipose-Derived Inflammation — A Sustained Inflammatory Load
Visceral adipose tissue in metabolic obesity actively secretes pro-inflammatory cytokines — including TNF-α, IL-1β, and IL-6 — that sustain systemic low-grade inflammation. This inflamed internal environment primes the immune system for the exaggerated inflammatory responses seen in HS. The result is that the threshold for lesion formation is lowered: minor follicular irritation triggers disproportionate inflammatory cascades that, in a metabolically healthy person, would resolve without consequence.
Gut Dysbiosis — The Amplifier
Metabolic dysfunction is closely linked to gut microbiome disruption. Insulin resistance and high-glycaemic dietary patterns alter microbial composition, increase gut permeability, and allow bacterial translocation that further amplifies systemic inflammatory load. This gut-skin axis means that poor gut health directly worsens HS activity — and that metabolic treatment without gut correction often produces incomplete results. In Ayurvedic terms, this accumulation of Ama (unprocessed metabolic waste) becomes the persistent fuel for Pitta and Rakta Dushti (blood-related inflammation).
Lymphatic Impairment — Drainage Failure
Obesity is associated with compromised lymphatic function: increased lymphatic load, reduced lymphatic contractility, and impaired drainage — particularly in the axillary and inguinal regions where HS most commonly presents. Lymphatic impairment means that inflammatory mediators and metabolic waste products accumulate locally rather than being efficiently cleared, sustaining the local inflammatory environment that drives lesion formation and delays healing. This is why obesity-linked HS so frequently presents as draining, chronic, and resistant to local treatment.
Structural Expression — Where the Skin Becomes the Visible End
Against this internal environment, the skin — particularly in intertriginous areas where heat, friction, and moisture concentrate — becomes the site of visible expression. Follicular blockage, abscess formation, and eventual tunnel development are not skin diseases in isolation. They are the local consequences of a sustained systemic inflammatory and hormonal state. This is why treating the skin alone — with antibiotics, steroids, or excision — does not interrupt the cycle: the tissue environment continues to generate new lesions.
The Metabolic Web Sustaining Obesity-Linked HS
Obesity-linked HS is not sustained by a single driver — it exists within an interconnected metabolic system where each element reinforces the others. Correcting one factor in isolation rarely produces sustained results.
Why Obesity-Linked HS Tends Toward Continuous, Not Cyclical, Activity
Many HS subtypes show cyclical recurrence — particularly hormonal HS, which tracks with menstrual or hormonal fluctuations. Obesity-linked HS more typically presents as continuous: lesions at varying stages of activity across multiple sites, without clear inter-flare periods. Understanding why this is matters for treatment.
Persistent Insulin Resistance Unlike a hormonal fluctuation that resolves after ovulation, insulin resistance is a chronic state. The elevated insulin and androgen levels it sustains are present continuously — meaning the internal driver of HS is never fully switched off between episodes.
Chronic Adipose Inflammation Visceral fat continuously secretes pro-inflammatory mediators. This sustained background inflammation keeps the immune system primed, maintaining a lower threshold for HS flares across all affected sites simultaneously — contributing to multifocal, continuous disease expression.
Multifocal Disease Distribution Because the internal driver is systemic rather than localised, obesity-linked HS typically affects multiple body regions. When one site appears to improve, another is often active — creating the experience of HS that is "always somewhere." This is the systemic driver expressing across multiple sites of susceptibility.
Lymphatic Backlog Impaired lymphatic function in intertriginous areas means that inflammatory mediators accumulate rather than clear between episodes. This lymphatic backlog sustains a local pro-inflammatory environment that perpetuates lesion activity even when systemic markers are not dramatically elevated.
Gut-Sustained Inflammatory Load Metabolic dysbiosis — where gut bacterial imbalance is driven by the same metabolic state as HS — means the gut continuously feeds systemic inflammation rather than helping resolve it. Without gut correction, the inflammatory environment that sustains HS is constantly being replenished from within.
Stress and Cortisol Amplification Chronic stress — which is disproportionately common in patients dealing with persistent pain and physical limitation — elevates cortisol, which worsens insulin resistance and further disrupts androgen balance. This creates a feedback loop where the burden of living with active HS worsens the metabolic state that drives it.
When a condition keeps recurring without clear inter-episode resolution, it usually means the internal state sustaining it has not changed — not that the condition itself is inherently treatment-resistant.
The Four Layers That Must Be Addressed in Obesity-Linked HS
Each of these drivers operates simultaneously in obesity-linked HS. Effective treatment maps which layers are most active in each individual case and addresses them in sequence — starting with the highest-burden factors first.
Layer 01 — Metabolic
Insulin Resistance and Glucose Dysregulation
Insulin resistance is the foundational metabolic driver. It creates the conditions for androgen excess, sustains adipose inflammation, and disrupts the gut environment. In obesity-linked HS, correcting insulin sensitivity is not optional — it is the prerequisite for meaningful clinical improvement. This requires targeted metabolic correction that goes beyond general dietary advice to address the specific patterns of insulin dysregulation in each patient.
Layer 02 — Hormonal
Androgen Excess and Endocrine Disruption
Hyperinsulinaemia-driven androgen excess is a consistent feature of obesity-linked HS. Elevated androgens drive the follicular changes central to lesion formation and explain the distribution of disease to androgen-sensitive sites. Hormonal correction — addressing not just overt PCOS-like features but the subtler patterns of insulin-androgen dysregulation — is an integral part of treatment, particularly in women but also relevant in male patients.
Layer 03 — Inflammatory / Immune
Systemic and Adipose-Derived Inflammation
The inflammatory load in obesity-linked HS has two sources: the systemic low-grade inflammation of the metabolic state, and the adipose-derived cytokine burden. Both must be progressively reduced. Anti-inflammatory approaches that work at the systemic level — gut restoration, detoxification support, metabolic correction — are more effective than approaches targeting inflammation at the skin surface alone.
Layer 04 — Gut and Lymphatic
Gut Dysbiosis and Lymphatic Clearance Failure
Gut restoration is essential in obesity-linked HS — both because gut dysbiosis amplifies systemic inflammation and because the gut plays a critical role in hormonal metabolism, including androgen clearance. Concurrently, lymphatic support in the areas of primary involvement — improving drainage and reducing local inflammatory backlog — helps interrupt the local recurrence cycle even as systemic correction is underway.
How Obesity-Linked HS Evolves Without Internal Correction
Obesity-linked HS typically progresses through recognisable stages — but often reaches advanced stages faster than hormonally-driven HS, due to the continuous (rather than cyclical) nature of the internal driver. Understanding progression helps clarify what becomes more difficult to reverse with delayed treatment.
Early Stage · Hurley I
Episodic Nodules, Multiple Sites
Painful nodules appearing at two or more body regions
Healing between episodes, but recurrence interval shortening
Often attributed to hygiene, friction, or diet alone
Metabolic markers may already show early insulin resistance
Internal correction at this stage produces the most complete outcomes
Intermediate Stage · Hurley II
Recurrent Abscesses, Early Tunnelling
Recurrent abscesses at multiple sites with minimal inter-episode resolution
Early sinus tract formation at primary locations
Chronic discharge beginning at one or more sites
Antibiotic courses providing diminishing returns
This is the most common stage at first presentation to EPOH
Advanced Stage · Hurley III
Continuous Disease, Established Fibrosis
Continuous multi-site disease with established tunnel networks
Fibrosis and scarring limiting mobility and causing chronic pain
Systemic metabolic impact significant: elevated inflammatory markers, metabolic syndrome features
Surgical intervention may address local lesions without resolving systemic drivers
Internal correction still relevant — goals shift toward stabilisation and quality of life improvement
Unless the underlying metabolic and inflammatory causes are addressed, obesity-linked HS may continue to progress — adding new sites, deepening existing lesions, and expanding structural damage — regardless of local treatment.
What Structured Treatment for Obesity-Linked HS Actually Addresses
The goal is not weight loss as an endpoint — it is correction of the metabolic environment that drives both obesity and HS. When the internal state changes, both conditions improve. This requires a structured, phase-based approach that targets each active driver in sequence.
The highest-priority first step is reducing the accumulated metabolic and inflammatory load that sustains continuous HS activity. This means addressing gut dysbiosis, supporting hepatic metabolic processing, and beginning to clear the systemic inflammatory burden that keeps the immune system in a primed state. This phase does not focus on weight — it focuses on creating an internal environment that is less hostile to healing.
Direct correction of insulin sensitivity is the metabolic foundation of treatment. This involves targeted formulations that improve cellular insulin response, combined with specific dietary and lifestyle adjustments calibrated to each patient's metabolic pattern. The aim is not a universal diet prescription — it is an individualised approach based on the specific nature of each patient's insulin dysregulation and inflammatory food triggers.
As insulin resistance improves, androgen excess begins to reduce — but targeted hormonal correction accelerates this and addresses adrenal contributions that persist beyond insulin normalisation. In women, this phase addresses the PCOS-adjacent hormonal pattern that most obesity-linked HS cases involve. In men, the adrenal and metabolic hormone components are the primary focus. Hormonal correction also supports gut-based androgen clearance.
As the internal environment stabilises, the focus shifts to supporting tissue repair and restoring lymphatic function in affected areas. Formulations that promote healing of established lesions, reduce fibrotic activity in early sinus tracts, and support lymphatic drainage help the body recover from the structural damage accumulated during active disease. This phase also addresses local skin integrity and barrier function.
The final phase focuses on maintaining the metabolic and hormonal correction achieved — preventing the return of the internal state that drives HS. This is not indefinite treatment; it is the establishment of a sustainable physiological baseline. Regular monitoring, seasonal adjustment, and continued lifestyle integration ensure that the gains of treatment are not reversed by the return of old patterns.
Herbal Formulations for Obesity-Linked HS — Designed Around the Metabolic Pattern
Because obesity-linked HS involves a specific configuration of metabolic, hormonal, and inflammatory drivers, the formulation strategy is built around these targets. Each formulation is personalised — adjusted to the individual's specific metabolic profile, dominant drivers, and disease stage.
Formulation 01
Metabolic Detox and Inflammatory Load Reduction
Targets the accumulated metabolic waste and inflammatory burden — improving liver function, gut barrier integrity, and systemic clearance pathways. This formulation reduces the background inflammatory state that keeps HS active between visible flares. It is the foundation of the treatment approach, as subsequent formulations work more effectively when this metabolic load has been reduced.
Formulation 02
Insulin Sensitivity and Blood Sugar Regulation
Formulations that directly improve cellular insulin response and support glucose metabolism — reducing the hyperinsulinaemia that drives androgen excess and sustains inflammation. This is a central formulation in obesity-linked HS treatment, often producing noticeable changes in lesion frequency and severity as insulin resistance begins to improve. Personalisation accounts for the specific pattern and degree of insulin dysregulation in each patient.
Formulation 03
Hormonal Balance and Androgen Correction
Targets androgen excess through multiple pathways: reducing insulin-driven androgen production, supporting hepatic androgen clearance, and stabilising adrenal function. This formulation is calibrated differently for women (where PCOS-adjacent patterns require specific endocrine support) and men (where adrenal and metabolic androgen contributions are the primary focus).
Formulation 04
Gut Restoration and Microbiome Rebalancing
Addresses the gut dysbiosis that amplifies inflammatory load and impairs hormonal clearance. This formulation improves gut barrier integrity, rebalances microbial composition, and reduces gut-origin inflammatory signals. Gut restoration is particularly important in obesity-linked HS because the metabolic state itself continuously disrupts the gut environment — making gut correction an ongoing rather than one-time intervention.
Formulation 05
Tissue Repair and Lymphatic Drainage Support
Supports healing of established lesions and early sinus tracts, reduces fibrotic progression, and promotes lymphatic clearance in affected areas. This formulation works most effectively once the systemic inflammatory and metabolic load has begun to reduce — allowing tissue repair processes to proceed without being continuously overwhelmed by new inflammatory signals.
Formulation 06
Metabolic Resilience and Recurrence Prevention Rasayana
A long-term adaptogenic and metabolic support formulation that consolidates the improvements achieved and strengthens the body's capacity to maintain metabolic balance without continuous intensive intervention. This formulation reduces the risk of relapse when dietary or lifestyle patterns shift, and supports sustained immune regulation — the physiological foundation of HS remission.
Lifestyle Variables That Directly Affect Obesity-Linked HS — Beyond Generic Advice
Lifestyle is not supplementary to treatment in obesity-linked HS — it is integral. But generic lifestyle advice — "eat less, move more, reduce stress" — is insufficient when specific metabolic patterns need targeted correction. The following reflects how lifestyle integration is approached in a structured, personalised way.
Diet
Metabolic Dietary Correction, Not Restriction
The dietary approach targets the specific food patterns that sustain insulin resistance and inflammatory load in each patient. This is not a universal "HS diet" — it involves identifying individual inflammatory triggers, managing glycaemic patterns, and supporting gut health through food choices. The aim is sustainable dietary adjustment that reduces metabolic burden without creating additional stress or dietary restriction that is difficult to maintain.
Movement
Graduated, Lesion-Aware Activity
Movement improves insulin sensitivity, supports lymphatic drainage, and reduces visceral fat over time — all directly beneficial for obesity-linked HS. However, activity recommendations must account for current lesion location and severity: high-impact, high-friction activity that irritates active lesions is counterproductive. Guidance is graduated to the patient's current capacity, with movement types chosen for their lymphatic and metabolic benefit without worsening local disease.
Stress Regulation
Breaking the Stress–Insulin–HS Loop
Chronic stress worsens insulin resistance through cortisol-mediated mechanisms, directly amplifying the primary driver of obesity-linked HS. Many patients dealing with continuous pain, physical limitation, and the social impact of HS experience significant chronic stress — creating a feedback loop where the condition worsens its own drivers. Effective stress regulation is approached practically: techniques that actually reduce cortisol burden in each patient's specific circumstances, not generic relaxation suggestions.
Sleep
Sleep Quality and Metabolic Recovery
Poor sleep directly worsens insulin resistance and elevates cortisol — both central drivers of obesity-linked HS. Patients with active disease frequently have disrupted sleep due to pain and discomfort, creating another feedback loop. Sleep architecture assessment and specific guidance on improving sleep quality form part of the integrated treatment approach, as metabolic recovery during sleep is essential for the systemic correction that treatment aims to achieve.
Other HS Presentations That Often Coexist
Obesity-linked HS is frequently multifocal — meaning multiple location-based subtypes are active simultaneously. Because the internal driver is systemic, treating the system addresses all active sites. Each location-based subtype linked below has its own specific profile within the shared metabolic framework.
If HS Keeps Recurring Despite Treatment, the Metabolic Pattern Has Not Been Addressed
A personalised evaluation identifies which metabolic, hormonal, and inflammatory drivers are sustaining your specific HS pattern — and builds a structured approach around correcting them. This is where continuous recurrence can begin to be interrupted rather than managed indefinitely.